Browse the evidence

Obesity is associated with many health risks, including hypertension, hyperlipidemia, T2D, CHD, stroke, gallbladder disease, osteoarthritis, sleep apnea, respiratory problems, and some cancers.

Healthcare practitioners should be aware of the extensive health risks associated with obesity.

52.9% of Semaglutide users reached the 2.4 mg dose compared to 77.6% of Tirzepatide users reaching 15 mg.

Practitioners should note the higher success rate of Tirzepatide in reaching the maintenance dose.

Non-optimized dosing was associated with higher estimated monthly plan costs.

Practitioners should consider the cost implications of dosing strategies.

Management of weight should be patient-centered and consider age, health conditions, medications, and reproductive potential.

Practitioners should tailor weight management strategies to individual patient needs and circumstances.

Key considerations when treating weight in women include the impact on sex-specific conditions and reproductive considerations of anti-obesity medications.

Practitioners should incorporate sex-specific and reproductive considerations into weight treatment plans.

Discontinuation of obesity medications often results in weight regain and reversal of health benefits.

Practitioners should monitor patients for weight regain after discontinuation and implement strategies to mitigate this.

Treatment would produce 75,800 quality-adjusted life-years valued at $7 billion.

Obesity treatment can significantly enhance life quality and longevity for Medicaid beneficiaries.

82.7% of participants received no further prescriptions for antiobesity medications (AOMs) after their initial prescription.

This indicates a potential gap in ongoing obesity management for these patients.

The overall certainty of evidence for the effects of tirzepatide on physical function was rated as moderate due to risk of bias and inconsistency across studies.

Practitioners should be aware of the moderate certainty of evidence when considering tirzepatide for improving physical function.

Global Guidelines for obesity management emphasize the incorporation of novel therapies and integration of standards of care with up-to-date evidence.

Clinicians should adopt these guidelines to improve obesity management globally.

GLP-1-Rezeptoragonisten sollten als Krankenkassenleistung angeboten werden.

Praktiker sollten die Möglichkeit in Betracht ziehen, GLP-1-Rezeptoragonisten in die Krankenkassenleistungen aufzunehmen.

Among 7,493 members, rates of persistence and adherence to treatment were 60.8% and 60.1%, respectively.

Practitioners should note that adherence to GLP-1 therapies is moderate in this population.

Member-specific factors associated with lower rates of persistence and adherence included male sex, age (<40 years), diabetes, and a lack of weight-related comorbidities.

Understanding these factors can help tailor interventions to improve adherence.

Both groups achieved comparable reductions in body weight after 12 weeks.

Weight loss can be achieved with both dietary interventions during Tirzepatide therapy.

Preliminary dose-dependent weight reductions were observed with KN069.

KN069 may help in achieving weight loss in this demographic.

Surgeons should recognize GLP-1 RAs as complementary tools within multidisciplinary obesity and metabolic care pathways.

Surgeons should integrate GLP-1 RAs into their treatment strategies for obesity management.

64.8% of patients with obstructive sleep apnea (OSA) presenting to a sleep surgery clinic met FDA-approved criteria for GLP-1 receptor agonist (RA) use.

Practitioners should consider that a significant portion of OSA patients may be eligible for GLP-1 RA treatment.

Tirzepatide treatment preserved lean mass and muscle function after 4 months.

Tirzepatide may help maintain muscle mass and function during weight loss in obese patients.

Whey and soy proteins can be part of a resistance training regimen, but findings should be interpreted with caution due to small sample size.

Practitioners should consider the potential benefits of protein supplementation while being aware of the limitations of the current evidence.

Energy availability decreased from 38 ± 3 kcal/kg/FFM to 18 ± 4 kcal/kg/FFM while energy expenditure increased from 24 ± 4 to 44 ± 15 met/h/week from PRE to END.

Practitioners should be aware of the significant changes in energy availability and expenditure during competition preparation.

There was no significant clinical aggravation of renal biomarkers in the studies reviewed.

Clinicians can be reassured that protein supplementation does not adversely affect renal biomarkers in this population.

The existing data on protein supplementation and kidney function is weakened by brief study periods and traditional biomarkers.

Future research should focus on longer study durations and advanced renal markers for better safety profiles.

Dysfunctional eating attitudes and behaviors (DEAB) are more concerning in the athletic population than in the general population.

Practitioners should be aware that athletes may exhibit higher levels of dysfunctional eating behaviors compared to non-athletes.

There is a need for assessment tools specifically adapted to the context of athletes to improve screening accuracy for DEAB.

Developing and validating tailored assessment tools can enhance the identification of DEAB in athletes.